Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2013 4
2016 1
2017 1
2018 1
2019 2
2021 1
2022 5
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
T cell co-stimulatory factors.
Greisen S, Kunder R, Deleuran B. Greisen S, et al. Among authors: kunder r. Rheumatology (Oxford). 2017 Jun 1;56(6):861-862. doi: 10.1093/rheumatology/kew276. Rheumatology (Oxford). 2017. PMID: 27402872 No abstract available.
International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis.
Chalhoub NE, Wenderfer SE, Levy DM, Rouster-Stevens K, Aggarwal A, Savani SI, Ruth NM, Arkachaisri T, Qiu T, Merritt A, Onel K, Goilav B, Khubchandani RP, Deng J, Fonseca AR, Ardoin SP, Ciurtin C, Kasapcopur O, Jelusic M, Huber AM, Ozen S, Klein-Gitelman MS, Appenzeller S, Cavalcanti A, Fotis L, Lim SC, Silva RM, Miramontes JR, Rosenwasser NL, Saad-Magalhaes C, Schonenberg-Meinema D, Scott C, Silva CA, Enciso S, Terreri MT, Torres-Jimenez AR, Trachana M, Al-Mayouf SM, Devarajan P, Huang B, Brunner HI; Childhood Arthritis and Rheumatology Research Alliance Lupus Nephritis Work Group and the Pediatric Rheumatology European Society Lupus Working Party. Chalhoub NE, et al. Arthritis Rheumatol. 2022 Feb;74(2):263-273. doi: 10.1002/art.41930. Epub 2022 Jan 4. Arthritis Rheumatol. 2022. PMID: 34279063 Free PMC article.
First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers.
Tang F, Kunder R, Chu T, Hains A, Nguyen A, McBride JM, Zhong Y, Santagostino S, Wilson M, Trenchak A, Chen L, Ly J, Moein A, Lewin-Koh N, Raghavan V, Osaghae U, Wynne C, Owen R, Place D. Tang F, et al. Among authors: kunder r. Clin Transl Sci. 2023 Sep;16(9):1653-1666. doi: 10.1111/cts.13576. Epub 2023 Jul 23. Clin Transl Sci. 2023. PMID: 37350225 Free PMC article. Clinical Trial.
Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases.
Yadav R, Sukumaran S, Lutman J, Mitra MS, Halpern W, Sun T, Setiadi AF, Neighbors M, Sheng XR, Yip V, Shen BQ, Liu C, Han L, Ovacik AM, Wu Y, Glickstein S, Kunder R, Arron JR, Pan L, Kamath AV, Stefanich EG. Yadav R, et al. Among authors: kunder r. J Pharm Sci. 2023 Nov;112(11):2910-2920. doi: 10.1016/j.xphs.2023.07.005. Epub 2023 Jul 8. J Pharm Sci. 2023. PMID: 37429356 Free article.
Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
Kunder R, Velyunskiy M, Dunne SF, Cho BK, Kanojia D, Begg L, Orriols AM, Fleming-Trujillo E, Vadlamani P, Vialichka A, Bolin R, Perrino JN, Roth D, Clutter MR, Zielinski-Mozny NA, Goo YA, Cristofanilli M, Mendillo ML, Vassilopoulos A, Horiuchi D. Kunder R, et al. Cell Chem Biol. 2022 Mar 17;29(3):358-372.e5. doi: 10.1016/j.chembiol.2021.08.011. Epub 2021 Sep 14. Cell Chem Biol. 2022. PMID: 34525344 Free PMC article.
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation.
Chen H, Kunder R, Zou Y, Staton T, Zhu R, Galanter J, Gugelmann H, Owen R, Grimbaldeston MA, Chang JK, Durk MR, Eliahu A, Wilson MS, Choy DF, Wilson M, Black M, Doppen M, Kung S, Oldfield K, Sparks J, Beasley R, Braithwaite I. Chen H, et al. Among authors: kunder r. Pulm Pharmacol Ther. 2022 Aug;75:102133. doi: 10.1016/j.pupt.2022.102133. Epub 2022 May 26. Pulm Pharmacol Ther. 2022. PMID: 35644305 Clinical Trial.
Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis.
Schanberg LE, Ramanan AV, De Benedetti F, Beukelman T, Eakin GS, Del Gaizo V, Ringold S, Vesely R, Schrandt S, Jaki T, Bili A, Chung JB, De Bono S, Douglass W, Enejosa JV, Kanik KS, Knobe K, Kunder R, Leite-Schnell JC, Suehiro RM, Wong RL, Mieszkalski KL, Marrow LC, Siebenaler K, Fraulo E, Kimura Y. Schanberg LE, et al. Among authors: kunder r. Arthritis Rheumatol. 2019 Dec;71(12):1976-1984. doi: 10.1002/art.41043. Epub 2019 Nov 1. Arthritis Rheumatol. 2019. PMID: 31313532
Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas.
Bharambe HS, Paul R, Panwalkar P, Jalali R, Sridhar E, Gupta T, Moiyadi A, Shetty P, Kazi S, Deogharkar A, Masurkar S, Yogi K, Kunder R, Gadewal N, Goel A, Goel N, Chinnaswamy G, Ramaswamy V, Shirsat NV. Bharambe HS, et al. Among authors: kunder r. Acta Neuropathol Commun. 2019 Apr 3;7(1):52. doi: 10.1186/s40478-019-0697-3. Acta Neuropathol Commun. 2019. PMID: 30944042 Free PMC article.
22 results